share_log

Clearmind Medicine | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(4.99%),Daniel B. Asher(4.99%), etc.

Clearmind Medicine | SC 13G/A:超過5%持股股東披露文件(修正)-Mitchell P. Kopin(4.99%),Daniel B. Asher(4.99%)等

SEC announcement ·  02/06 09:57
Moomoo AI 已提取核心訊息
An amendment to Schedule 13G has been filed with the United States Securities and Exchange Commission by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, reporting a change in their holdings of Clearmind Medicine Inc. common shares. As of December 31, 2023, the reporting persons collectively hold 88,925 shares, representing approximately 4.99% of the company's common stock. This ownership includes shares issuable upon the exercise of two warrants held by Intracoastal Capital LLC. The amendment, filed on February 6, 2024, indicates that the shares were not acquired for the purpose of changing or influencing the control of Clearmind Medicine Inc. and are not held in connection with any transaction having that purpose or effect.
An amendment to Schedule 13G has been filed with the United States Securities and Exchange Commission by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, reporting a change in their holdings of Clearmind Medicine Inc. common shares. As of December 31, 2023, the reporting persons collectively hold 88,925 shares, representing approximately 4.99% of the company's common stock. This ownership includes shares issuable upon the exercise of two warrants held by Intracoastal Capital LLC. The amendment, filed on February 6, 2024, indicates that the shares were not acquired for the purpose of changing or influencing the control of Clearmind Medicine Inc. and are not held in connection with any transaction having that purpose or effect.
米切爾·科平、丹尼爾·阿舍爾和Intracoastal Capital LLC已向美國證券交易委員會提交了附表13G的修正案,報告了他們持有的Clearmind Medicine Inc.普通股的變化。截至2023年12月31日,申報人共持有88,925股股票,約佔公司普通股的4.99%。該所有權包括行使Intracoastal LLC持有的兩份認股權證後可發行的股份。該修正案於2024年2月6日提交,表明收購這些股份不是爲了改變或影響Clearmind Medicine Inc.的控制權,也不是與任何具有該目的或效果的交易有關而持有的。
米切爾·科平、丹尼爾·阿舍爾和Intracoastal Capital LLC已向美國證券交易委員會提交了附表13G的修正案,報告了他們持有的Clearmind Medicine Inc.普通股的變化。截至2023年12月31日,申報人共持有88,925股股票,約佔公司普通股的4.99%。該所有權包括行使Intracoastal LLC持有的兩份認股權證後可發行的股份。該修正案於2024年2月6日提交,表明收購這些股份不是爲了改變或影響Clearmind Medicine Inc.的控制權,也不是與任何具有該目的或效果的交易有關而持有的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息